短肠综合征全球市场研究报告——2023-2030 年行业分析、规模、份额、增长、趋势和预测

全球对短肠综合征市场的需求将从 2022 年的 8.4112 亿美元增长到 2030 年的近 55.2245 亿美元，在 2023-2030 研究期间的复合年增长率为 26.52%。预计将达到

短肠综合征 (SBS) 是一种疾病，其中小肠或小肠的一部分通过手术切除或出现功能障碍，从而导致营养不良和腹泻。 小肠负责从食物中吸收营养，如果缺少任何一个部分，就无法吸收足够的身体所需的营养。 SBS 可由克罗恩病、癌症和小肠损伤等疾病引起。 SBS 的症状包括营养不良、腹泻、腹痛和体重减轻。 在严重的情况下，可能需要肠外营养（肠外营养）来维持健康。

市场动态：

由于克罗恩病和癌症等导致肠切除的疾病患病率增加等因素，短肠综合征的发病率正在增加。 这推动了对 SBS 药物的需求。 新手术技术的发展以及新药和设备的引进正在推动 SBS 市场的增长。 这些进展改善了 SBS 患者的预后和生活质量。 医疗保健专业人员和公众对短肠综合征的认识不断提高，这推动了对 SBS 治疗的需求。 这种认识导致了 SBS 的早期诊断和更有效的治疗。 政府和私人机构增加对 SBS 研究的投资正在推动 SBS 市场的增长。 这项投资导致了新的、更有效的 SBS 治疗方法的开发。 对于 SBS 的有效治疗，仍然存在大量未满足的医疗需求。 这推动了对新的和改进的 SBS 处理的需求，预计这将继续推动 SBS 市场的增长。

这份研究报告解释了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还对全球短肠综合症市场的每个细分市场进行了全面评估。 短肠综合征行业的发展和趋势为这项研究提供了一种整体方法。

市场细分：

短肠综合征市场细分提供按国家和地区划分的详细数据，以帮助确定产品和服务的目标受众和未来商机。

按产品

• 胰高血糖素样□ (GLP2)
• 成长和谐
• 谷氨□胺
• 其他

按分布

• 医院药房
• 零售药房
• 在线药店

按地区分析：

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲、中东和非洲短肠综合症市场当前和未来的需求。 此外，我们还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 短肠综合征市场的主要参与者是武田製药有限公司、默克公司、Zealand Pharma A/S、OxThera、VectivBio AG、9 Meters Biopharma Inc、Nutrinia Ltd、Hanmi Pharm Co Ltd、Pharmascience Inc。竞争格局，包括各种战略发展，如战略併购、未来能力、合作伙伴关係、财务概览、合作、新产品开发和新产品发布。

如果您有定制要求，请联繫我们。 我们的研究团队可以根据您的需要提供定制报告。

内容

第一章前言

• 本报告的内容
  • 目的
  • 目标受众
  • 独特的销售主张 (USP) 及其提供的内容
• 调查范围
• 调查方法
  • 市场调研过程
  • 市场研究方法

第 2 章执行摘要

• 市场亮点
• 全球市场概况

第 3 章短肠综合症 - 行业分析

• 简介 - 市场动态
• 市场驱动力
• 市场製约因素
• 市场机会
• 行业趋势
• 波特的五力分析
• 市场吸引力分析
  • 按产品分类的市场吸引力分析
  • 市场吸引力分析：按分布
  • 市场吸引力分析：按地区

第四章价值链分析

• 价值链分析
• 原材料分析
  • 原材料清单
  • 原材料製造商列表
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直接营销
  • 间接营销
  • 营销渠道趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章全球短肠综合症产品市场分析

• 产品概览
• 实际数据和预测数据
• 按产品分析
• 胰高血糖素样□ (GLP2)
• 成长和谐
• 谷氨□胺
• 其他

第 7 章全球短肠综合征市场分布分析

• 分布概览
• 过去和未来的数据
• 分布分析
• 医院药房
• 零售药房
• 在线药店

第 8 章全球短肠综合症市场分析：按地区

• 区域展望
• 简介
• 北美销售分析
  • 概览、历史和预测销售分析
  • 北美各部门的销售分析
  • 北美销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史和预测销售分析
  • 按细分市场进行的欧洲销售分析
  • 按国家/地区划分的欧洲销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 其他欧洲销售分析
• 亚太地区销售分析
  • 概览、历史和未来销售分析
  • 亚太地区各部门的销售分析
  • 亚太国家/地区销售分析
  • 在中国的销售分析
  • 印度销售分析
  • 日本的销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 其他亚太地区销售分析
• 拉丁美洲销售分析
  • 概览、历史和未来销售分析
  • 拉丁美洲各部门的销售分析
  • 拉丁美洲国家/地区的销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利的销售分析
  • 其他拉丁美洲销售分析
• 中东和非洲销售分析
  • 概览、历史和未来销售分析
  • 中东/非洲地区的销售分析
  • 中东和非洲国家/地区的销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 其他中东和非洲销售分析

第 9 章短肠综合症公司的竞争格局

• 短肠综合征市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第十章公司简介

• 顶级公司的市场份额分析
• 市场集中度
• 武田製药有限公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期发展状况
• 默克公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Zealand Pharma A/S
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• OxThera
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Vectiv 生物公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 9 米生物製药公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Nutrinia 有限公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 韩美製药有限公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Pharmascience Inc.
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期趋势

注意：公司简介中的财务细节和近期发展基于可用信息，可能不包括私营公司。

The global demand for Short Bowel Syndrome Market is presumed to reach the market size of nearly USD 5522.45 MN by 2030 from USD 841.12 MN in 2022 with a CAGR of 26.52% under the study period 2023 - 2030.

Short Bowel Syndrome or SBS is a condition in which the small intestine or its portion is surgically removed or is not functioning properly, causing malnutrition and diarrhoea. The small intestine is the body part responsible for absorbing nutrients from food, and when a portion of it is missing, the body is unable to absorb enough nutrients to meet its needs. SBS can result due to conditions including Crohn's disease, cancer, and injury to the small intestine. Symptoms of SBS may include malnutrition, diarrhoea, abdominal pain, and weight loss. In severe cases, patients may require intravenous nutrition (known as parenteral nutrition) to maintain their health. 

Market Dynamics:

The incidence of Short Bowel Syndrome is increasing due to factors such as the increasing prevalence of conditions that lead to bowel resection, such as Crohn's disease and cancer. This is driving the demand for SBS treatments. Development of new surgical techniques and the introduction of new drugs and devices are driving the growth of the SBS market. These advances are leading to better patient outcomes and improved quality of life for SBS patients. The growing awareness about Short Bowel Syndrome, both among healthcare professionals and the general public, is driving the demand for SBS treatments. This awareness is leading to earlier diagnosis and more effective treatment of SBS. Increased investment in SBS research, both by the government and private organizations, is driving the growth of the SBS market. This investment is leading to the development of new, more effective SBS treatments. There is a significant medical need which has not been met for effective treatments for SBS. This is driving the demand for new and improved SBS treatments and is expected to continue to drive the growth of the SBS market in the future.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of short bowel syndrome. The growth and trends of short bowel syndrome industry provide a holistic approach to this study. 

Market Segmentation:

This section of the short bowel syndrome market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Product

• Glucagon-Like Peptide (GLP2)
• Growth Harmone
• Glutamine
• Others

By Distribution

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Short Bowel Syndrome market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the short bowel syndrome market include Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc, Nutrinia Ltd., Hanmi Pharm Co Ltd, Pharmascience Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . SHORT BOWEL SYNDROME - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Distribution
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY PRODUCT

• 6.1 Overview by Product
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product
• 6.4 Glucagon-like Peptide (GLP2) Historic and Forecast Sales by Regions
• 6.5 Growth Harmone Historic and Forecast Sales by Regions
• 6.6 Glutamine Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY DISTRIBUTION

• 7.1 Overview by Distribution
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE SHORT BOWEL SYNDROME COMPANIES

• 9.1. Short Bowel Syndrome Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF SHORT BOWEL SYNDROME INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Takeda Pharmaceutical Company Limited
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Merck KGaA
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Zealand Pharma A/S
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. OxThera
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. VectivBio AG
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. 9 Meters Biopharma Inc
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Nutrinia Ltd.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Hanmi Pharm Co Ltd
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Pharmascience Inc
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• Glucagon-like Peptide (GLP2) Market Sales by Geography (USD MN)
• Growth Harmone Market Sales by Geography (USD MN)
• Glutamine Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Distribution (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Short Bowel Syndrome Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Short Bowel Syndrome Report
• Market Research Process
• Market Research Methodology
• Global Short Bowel Syndrome Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Distribution
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• Glucagon-like Peptide (GLP2) Market Sales by Geography (USD MN)
• Growth Harmone Market Sales by Geography (USD MN)
• Glutamine Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.